/PMN
PMN Stock - ProMIS Neurosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$8.55+2.33%
+$0.20 (+2.33%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+110.5%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PMN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.46 – $8.64
TARGET (TP)$18.00
STOP LOSS$7.87
RISK/REWARD1:13.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.04
52W High$39.75
52W Low$6.27
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $8,138.696 | $1,565 |
| Gross Profit | N/A | $-10,444,957 | N/A | $-5,843,329.304 | $-3,181,584 |
| Gross Margin | N/A | N/A | N/A | -71796.9% | -203296.1% |
| Operating Income | $-16,827,478 | $-18,897,693 | $-23,379,912 | $-8,249,672.946 | $-5,662,392 |
| Net Income | $2.78M | $-17,506,142 | $-18,062,263 | $-9,657,559.097 | $-5,662,392 |
| Net Margin | N/A | N/A | N/A | -118662.2% | -361814.2% |
| EPS | $2.75 | $-35.50 | $-42.50 | $-41.75 | $-23.25 |
Company Overview
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PMNBeat Rate
50%
Last 10 quarters
Avg Surprise
-19.4%
EPS vs Estimate
Beats / Misses
5/5
Last 12 quarters
Latest EPS
$-6.00
Q4 2025
EPS Surprise History
Q2 24
+47.1%
$-0.09vs$-0.17
Q2 24
+5.0%
$-0.19vs$-0.20
Q3 24
+7.1%
$-0.13vs$-0.14
Q4 24
-100.0%
$-0.14vs$-0.07
Q1 25
+85.7%
$-0.02vs$-0.14
Q2 25
-75.0%
$-0.21vs$-0.12
Q3 25
-31.8%
$-0.29vs$-0.22
Q4 25
-60.0%
$-6.00vs$-3.75
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-4.22 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-3.75 | $-6.00 | -60.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.22 | $-0.29 | -31.8% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.12 | $-0.21 | -75.0% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.14 | $-0.02 | +85.7% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.07 | $-0.14 | -100.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.14 | $-0.13 | +7.1% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.20 | $-0.19 | +5.0% | ✓ BEAT |
Q2 2024 | Apr 1, 2024 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.33 | $-0.19 | +42.4% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | — | $-0.27 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.58 | — | — |
Q1 2023 | Mar 8, 2023 | — | $-0.90 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-0.85 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-0.38 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.60 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.30 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.16 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.04 | — | — |
Q2 2021 | May 14, 2021 | $-0.45 | $-0.98 | -114.9% | ✗ MISS |
Latest News
ProMIS Neurosciences Completes Enrollment Of 144 Patients In PRECISE-AD Phase 1b Clinical Trial, Evaluating PMN310, Therapeutic Antibody Candidate For Treatment Of AD
📈 PositiveBenzinga•Dec 18, 2025, 12:33 PM•Also:
ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk
📈 PositiveBenzinga•Dec 10, 2025, 12:46 PM
HC Wainwright & Co. Maintains Buy on ProMIS Neurosciences, Raises Price Target to $18
📈 PositiveBenzinga•Dec 1, 2025, 03:59 PM•Also:
ProMIS Neurosciences Highlights New Peer-Reviewed Publication Showing Plasma pTau as Predictive Early Endpoint in Alzheimer's Trials Supporting PRECISE-AD
📈 PositiveBenzinga•Dec 1, 2025, 12:40 PM•Also:
ProMIS Neurosciences Highlights Plasma pTau As Early Predictor In PRECISE-AD Trial, Publication Reinforces Biomarker-Driven Design Ahead of Q2 2026 Interim Readout
📈 PositiveBenzinga•Dec 1, 2025, 12:37 PM•Also:
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 28, 2025, 01:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 27, 2025, 12:50 AM
Shares of ProMIS Neurosciences are trading lower after the company announced 1-for-25 reverse stock split.
📉 NegativeBenzinga•Nov 24, 2025, 05:12 PM•Also:
ProMIS Neurosciences to execute 1-for-25 reverse stock split
📉 NegativeSeeking Alpha•Nov 24, 2025, 01:30 PM•Also:
ProMIS Neurosciences Announces 1-For-25 Reverse Stock Split, Effective Nov. 28
📉 NegativeBenzinga•Nov 24, 2025, 01:01 PM•Also:
HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $4 Price Target
📈 PositiveBenzinga•Nov 21, 2025, 11:18 AM•Also:
Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $5
➖ NeutralBenzinga•Nov 18, 2025, 02:49 PM•Also:
ProMIS Neurosciences shares are trading higher. The company reported Q3 financial results.
📈 PositiveBenzinga•Nov 12, 2025, 04:56 PM•Also:
ProMIS Neurosciences Q3 EPS $(0.24), Inline
➖ NeutralBenzinga•Nov 12, 2025, 12:15 PM•Also:
ProMIS Neurosciences Files Prospectus Of 28.2M Common Shares Offering Relates To Resale By Selling Securityholders
➖ NeutralBenzinga•Sep 4, 2025, 08:37 PM•Also:
PMN stock has given up its prior gain. PMN up: ProMIS Neurosciences shares were trading higher after the Data and Safety Monitoring Board recommended the company proceed to the third dose escalation cohort in its PRECISE-AD Phase 1b Alzheimer's trial.
📈 PositiveBenzinga•Sep 3, 2025, 12:25 PM•Also:
PMN up: ProMIS Neurosciences shares are trading higher after the Data and Safety Monitoring Board recommended the company proceed to the third dose escalation cohort in its PRECISE-AD Phase 1b Alzheimer's trial.
📈 PositiveBenzinga•Sep 3, 2025, 11:08 AM•Also:
ProMIS Neurosciences Announces Data And Safety Monitoring Board For Its PRECISE-AD Phase 1b Alzheimer's Trial Recommended Co. Proceed To Third Dose Escalation Cohort
📈 PositiveBenzinga•Sep 3, 2025, 11:03 AM•Also:
Frequently Asked Questions about PMN
What is PMN's current stock price?
ProMIS Neurosciences, Inc. (PMN) is currently trading at $8.55 per share. The stock has moved +2.33% today.
What is the analyst price target for PMN?
The average analyst price target for PMN is $18.00, based on 1 analyst.
What sector is ProMIS Neurosciences, Inc. in?
ProMIS Neurosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PMN's market cap?
ProMIS Neurosciences, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does PMN pay dividends?
No, ProMIS Neurosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
BRTX
BioRestorative Therapies, Inc.
$1.15
Mkt Cap: $0.0B
EDSA
Edesa Biotech, Inc.
$1.48
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
LPCN
Lipocine Inc.
$4.25
Mkt Cap: $0.0B
MPLT
MapLight Therapeutics, Inc.
$20.55
Mkt Cap: $0.0B
OSRH
OSR Holdings, Inc.
$0.65
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to PMN for comparison